Florence Joly
Impact in
- Reproductive Medicine top 0.1%
- Ovarian cancer diagnosis and treatment
- Oncology top 0.2%
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Cancer survivorship and care
Papers in
-
- Cancer-related cognitive impairment studies 64
- Renal cell carcinoma treatment 27
- Prostate Cancer Treatment and Research 26
-
- Ovarian cancer diagnosis and treatment 42
- Co-authors
- Marie Lange (48 shared papers)Hélène Castel (19 shared papers)Janette L. Vardy (4 shared papers)David Saadoun (2 shared papers)David Klatzmann (2 shared papers)Michèlle Rosenzwajg (2 shared papers)Patrice Cacoub (2 shared papers)D. Sène (2 shared papers)
- Journals
- Annals of Oncology (38 papers)International Journal of Gynecological Cancer (16 papers)European Journal of Cancer (15 papers)Gynecologic Oncology (14 papers)The Lancet Oncology (13 papers)
- Partner nations
- FranceLuxembourgUnited States
In The Last Decade
Florence Joly
318 papers receiving 17.3k citations
Florence Joly's Hit Papers
Peers
Comparison fields: 5 of 151
- Reproductive Medicine 2.9k
- Oncology 6.3k
- Obstetrics and Gynecology 1.2k
- Pulmonary and Respiratory Medicine 4.6k
- Cancer Research 1.2k
Countries citing papers authored by Florence Joly
This map shows the geographic impact of Florence Joly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florence Joly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florence Joly more than expected).
Fields of papers citing papers by Florence Joly
This network shows the impact of papers produced by Florence Joly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florence Joly. The network helps show where Florence Joly may publish in the future.
Co-authors
The 25 scholars most cited alongside Florence Joly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 333 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 1562 |
| 2 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 1394 |
| 3 | Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial Hit paper breakdown → | 2015 | 700 |
| 4 | Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis Hit paper breakdown → | 2011 | 631 |
| 5 | Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2013 | 571 |
| 6 | Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors Hit paper breakdown → | 2019 | 489 |
| 7 | Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 488 |
| 8 | Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2020 | 400 |
| 9 | Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2022 | 400 |
| 10 | Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial Hit paper breakdown → | 2015 | 375 |
| 11 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2021 | 319 |
| 12 | Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial Hit paper breakdown → | 2014 | 302 |
| 13 | ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* Hit paper breakdown → | 2023 | 289 |
| 14 | 2018 | 272 | |
| 15 | ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 232 |
| 16 | 2016 | 230 | |
| 17 | 2018 | 199 | |
| 18 | 2012 | 191 | |
| 19 | 2005 | 185 | |
| 20 | 2014 | 176 |
About Florence Joly
Florence Joly is a scholar working on Pulmonary and Respiratory Medicine, Reproductive Medicine, Oncology, Obstetrics and Gynecology and Genetics, having authored 333 papers that have together received 17.7k indexed citations. Recurring topics across this work include Cancer-related cognitive impairment studies (64 papers), Ovarian cancer diagnosis and treatment (42 papers), Renal cell carcinoma treatment (27 papers), Prostate Cancer Treatment and Research (26 papers), Endometrial and Cervical Cancer Treatments (25 papers), Cancer survivorship and care (24 papers), Bladder and Urothelial Cancer Treatments (22 papers) and PARP inhibition in cancer therapy (21 papers). The work is most often cited by research in Reproductive Medicine (2.9k citations), Oncology (6.3k citations), Obstetrics and Gynecology (1.2k citations), Pulmonary and Respiratory Medicine (4.6k citations) and Cancer Research (1.2k citations). Florence Joly has collaborated with scholars based in France, Luxembourg and United States. Frequent co-authors include Marie Lange, Hélène Castel, Janette L. Vardy, David Saadoun, David Klatzmann, Michèlle Rosenzwajg, Patrice Cacoub, D. Sène, Martine Dubois and Laure Tron. Their work appears in journals such as Annals of Oncology, International Journal of Gynecological Cancer, European Journal of Cancer, Gynecologic Oncology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.